After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Researchers used brain expression data from mice with well-documented sleep traits to identify gene networks that overlap with those in human depression.
In an epigenome-wide association study of depression, the researchers tied DNA methylation to disease symptoms and suggested a role for axon guidance disruption.
This could mean that clinical boundaries between psychiatric disorders might not reflect their underlying biology, Brainstorm Consortium researchers said.
While a randomized-controlled trial is underway, Genomind hopes data from a new case-control study will convince insurers its PGx test can reduce healthcare utilization costs.
Researchers described diet-related patterns of gut microbial diversity, microbiome ties to psychiatric disease, and more.
The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.
Genetic tests may help psychiatrists choose which drugs to start their patients on, the Wall Street Journal reports.
Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.
A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.
Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.
In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.